151 related articles for article (PubMed ID: 9072003)
21. Novel p21WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas.
Malkowicz SB; Tomaszewski JE; Linnenbach AJ; Cangiano TA; Maruta Y; McGarvey TW
Oncogene; 1996 Nov; 13(9):1831-7. PubMed ID: 8934528
[TBL] [Abstract][Full Text] [Related]
22. Expression of p21WAF1/CIP1 in fetal and adult tissues: simultaneous analysis with Ki67 and p53.
Mateo MS; Saez AI; Sanchez-Beato M; Garcia P; Sanchez-Verde L; Martinez JC; Orradre JL; Piris MA
J Clin Pathol; 1997 Aug; 50(8):645-53. PubMed ID: 9301547
[TBL] [Abstract][Full Text] [Related]
23. P53 expression in Reed-Sternberg cells does not correlate with gene mutations in Hodgkin's disease.
Elenitoba-Johnson KS; Medeiros LJ; Khorsand J; King TC
Am J Clin Pathol; 1996 Dec; 106(6):728-38. PubMed ID: 8980348
[TBL] [Abstract][Full Text] [Related]
24. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
Landers JE; Cassel SL; George DL
Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
[TBL] [Abstract][Full Text] [Related]
25. Elevated levels of MDM-2 and p53 expression are associated with high grade non-Hodgkin's lymphomas.
Finnegan MC; Goepel JR; Royds J; Hancock BW; Goyns MH
Cancer Lett; 1994 Nov; 86(2):215-21. PubMed ID: 7982210
[TBL] [Abstract][Full Text] [Related]
26. Expression of the p53 induced tumor suppressor p21waf1/cip1 in ovarian carcinomas: correlation with p53 and Ki-67 immunohistochemistry.
Werness BA; Jobe JS; DiCioccio RA; Piver MS
Int J Gynecol Pathol; 1997 Apr; 16(2):149-55. PubMed ID: 9100069
[TBL] [Abstract][Full Text] [Related]
27. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
[TBL] [Abstract][Full Text] [Related]
28. Human non-Hodgkin's lymphomas overexpress a wild-type form of p53 which is a functional transcriptional activator of the cyclin-dependent kinase inhibitor p21.
Maestro R; Gloghini A; Doglioni C; Piccinin S; Vukosavljevic T; Gasparotto D; Carbone A; Boiocchi M
Blood; 1997 Apr; 89(7):2523-8. PubMed ID: 9116298
[TBL] [Abstract][Full Text] [Related]
29. The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target.
Picksley SM; Spicer JF; Barnes DM; Lane DP
Acta Oncol; 1996; 35(4):429-34. PubMed ID: 8695156
[TBL] [Abstract][Full Text] [Related]
30. The carboxy terminus of p53 mimics the polylysine effect of protein kinase CK2-catalyzed MDM2 phosphorylation.
Guerra B; Götz C; Wagner P; Montenarh M; Issinger OG
Oncogene; 1997 Jun; 14(22):2683-8. PubMed ID: 9178766
[TBL] [Abstract][Full Text] [Related]
31. Expression of p21WAF1/CIP1 in colorectal adenomas and adenocarcinomas and its correlation with p53 protein expression.
Yasui W; Akama Y; Yokozaki H; Semba S; Kudo Y; Shimamoto F; Tahara E
Pathol Int; 1997 Jul; 47(7):470-7. PubMed ID: 9234386
[TBL] [Abstract][Full Text] [Related]
32. Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease.
Chilosi M; Doglioni C; Menestrina F; Montagna L; Rigo A; Lestani M; Barbareschi M; Scarpa A; Mariuzzi GM; Pizzolo G
Blood; 1994 Dec; 84(12):4295-300. PubMed ID: 7994045
[TBL] [Abstract][Full Text] [Related]
33. p53, WAF1/CIP1 and mdm2 expression in skin lesions associated with human papillomavirus and human immunodeficiency virus.
Arany I; Yen A; Tyring SK
Anticancer Res; 1997; 17(2B):1281-5. PubMed ID: 9137486
[TBL] [Abstract][Full Text] [Related]
34. Growth factor modulation of p53-mediated growth arrest versus apoptosis.
Canman CE; Gilmer TM; Coutts SB; Kastan MB
Genes Dev; 1995 Mar; 9(5):600-11. PubMed ID: 7698649
[TBL] [Abstract][Full Text] [Related]
35. Expression of p53 and mdm-2 proteins in Hodgkin's Disease. Absence of correlation with the presence of Epstein-Barr virus.
Tzardi M; Kouvidou C; Panayiotides I; Koutsoubi K; Stefanaki K; Giannikaki E; Darivianaki K; Zois M; Eliopoulos G; Kakolyris S; Delides G; Rontogianni D; Kanavaros P
Anticancer Res; 1996; 16(5A):2813-9. PubMed ID: 8917390
[TBL] [Abstract][Full Text] [Related]
36. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas.
Skomedal H; Kristensen GB; Abeler VM; Børresen-Dale AL; Tropé C; Holm R
J Pathol; 1997 Feb; 181(2):158-65. PubMed ID: 9120719
[TBL] [Abstract][Full Text] [Related]
37. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma.
Gorgoulis VG; Zoumpourlis V; Rassidakis GZ; Karameris A; Rassidakis AN; Spandidos DA; Kittas C
J Pathol; 1996 Oct; 180(2):129-37. PubMed ID: 8976869
[TBL] [Abstract][Full Text] [Related]
38. Discordance between accumulated p53 protein level and its transcriptional activity in response to u.v. radiation.
Lu X; Burbidge SA; Griffin S; Smith HM
Oncogene; 1996 Jul; 13(2):413-8. PubMed ID: 8710381
[TBL] [Abstract][Full Text] [Related]
39. Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene.
Facher EA; Becich MJ; Deka A; Law JC
Cancer; 1997 Jun; 79(12):2424-9. PubMed ID: 9191533
[TBL] [Abstract][Full Text] [Related]
40. p53 functional impairment and high p21waf1/cip1 expression in human T-cell lymphotropic/leukemia virus type I-transformed T cells.
Cereseto A; Diella F; Mulloy JC; Cara A; Michieli P; Grassmann R; Franchini G; Klotman ME
Blood; 1996 Sep; 88(5):1551-60. PubMed ID: 8781409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
